Late cardiotoxicity related to HER2-targeted cancer therapy

Late cardiotoxicity related to HER2-targeted cancer therapy

Abstract Long-term anti-HER2 therapy in metastatic HER2 + cancers is increasing, but data about the incidence and risk factors for developing late Cancer therapy-related cardiac dysfunction (CTRCD) are missing. We conducted a single-centre, retrospective analysis of a cohort of late anti-HER2 relate...

Full description

Bibliographic Details
Main Authors: Isabelle Senechal, Maria Sol Andres, Jieli Tong, Ylenia Perone, Sivatharshini Ramalingam, Muhummad Sohaib Nazir, Stuart D Rosen, Nicholas Turner, Alistair Ring, Alexander R Lyon
Format: Article
Language:English
Published: BMC 2024-03-01
Series:Cardio-Oncology
Subjects:
Breast cancer
Cardio-oncology
Cardiotoxicity
Left ventricular dysfunction
HER2-targeted therapy
Online Access:https://doi.org/10.1186/s40959-024-00215-3

Internet

https://doi.org/10.1186/s40959-024-00215-3

Similar Items